Table 2. Univariate analysis of the survival predictive variables in patients with malignant pleural effusion of lung adenocarcinoma.
| |
Survival (days)* |
|
|
|---|---|---|---|
| Variable | YES | NO | p |
|
Sex (men) Age (> 67 y) p16/INK4a HPM |
215 (61 - 439) 102 (0 - 237) 157 (45 - 436) |
348 (80 - 582) 412 (359 - 465) 312 (72 - 479) |
0.5+ 0.1^ 0.5^ |
|
BRCA1 HPM |
239 (92 - 416) |
354 (45 - 582) |
0.7^ |
|
RARβ HPM |
366 (89 - 551) |
215 (58 - 420) |
0.3^ |
|
MGMT HPM Lack of HPM in any gene HPM in at least 2 genes HPM in at least 3 genes |
275 (92 - 517) 55 (14 - 226) 322 (60 - 508) 166 (69 - 284) |
287 (50 - 425) 322 (95 - 500) 230 (63 - 429) 348 (64 - 495) |
0.4^ 0.003+ 0.7^ 0.9^ |
|
pH (≤ 7.28) |
202 (54 - 347) |
374 (85 - 509) |
0.5^ |
|
Glucose (≤ 60 mg/dL) |
78 (28 - 194) |
380 (89 - 504) |
0.1^ |
|
LDH (≥ 1000 UI/L) |
302 (89 -486) |
275 (56 - 437) |
0.5^ |
|
Karnofsky index (≤ 70) |
85 (6 - 468) |
302 (78 - 468) |
0.1+ |
|
Charlson index (≥ 3) |
142 (28 - 236) |
348 (65 - 495) |
0.04 |
|
No oncological treatment |
15 (9 - 102) |
374 (174 - 509) |
< 0.001+ |
| Distant metastasis | 211 (40 - 473) | 348 (97 - 466) | 0.2^ |
HPM, hypermethylation of the promoter region; LDH, lactate dehydrogenase. *, Expressed as median (interquartile range). ^Breslow or +Log-Rank